# IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD

> **NCT01516294** · NA · UNKNOWN · sponsor: **Oraya Therapeutics, Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Polypoidal Chorodial Vasculopathy
- Age Related Macular Degeneration

## Interventions

- **RADIATION:** Iray

## Key facts

- **NCT ID:** NCT01516294
- **Lead sponsor:** Oraya Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2013-03
- **Final completion:** 2014-03
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2012-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516294, "IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01516294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*